Lemon_tm
- Insmed (INSM) is down ~17% in after-hours trading Monday after saying it will end development of brensocatib for chronic rhinosinusitis without nasal polyps after the candidate failed to meet primary and secondary endpoints in a phase 2b study.
- The study enrolled